RxDoctor Payments DataLook up a doctor →

Jeanne Lomas, DO

Allergy & Immunology · Amherst, NYNPI 1366684557

Payments from drug & device makers

$305,951in general payments, 2019–2025

Across 457 payments — averaging $669.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$178K
  • Sanofi US Services Inc.$66K
  • AstraZeneca$34K
  • GSK$14K
  • Sanofi$7K
  • ARS Pharmaceuticals Operations, Inc.$2K
  • plus $5K from 25 others
$482in research payments, 2019–2025

Across 7 payments — averaging $68.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$482

What the payments were for

  • Consulting fees$1,82510%
  • Speaking & faculty fees$5,44831%
  • Travel & lodging$8575%
  • Food & beverage$9,41053%
  • Education$981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$305,951 in reported general payments places this provider in the 90th percentile of 320 allergy & immunology providers in New York.

See all allergy & immunology providers in New York

Medicare billing

Part B allowed, 2024
$11,158
Medicare patients
77
Services billed
638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab11$40,844
Breo ElliptaFluticasone/Vilanterol12$5,586
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$4,161
SymbicortBudesonide/Formoterol Fumarate15$3,820
Azelastine Hcl30$1,000
Ipratropium Bromide36$834
Montelukast Sodium33$638
Albuterol Sulfate HfaAlbuterol Sulfate17$619
Famotidine31$437
Fluticasone Propionate40$430
Hydroxyzine Hcl12$163
Prednisone18$29

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$13,762$5,58612 claims
AstraZenecaSymbicort$33,866$3,82015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 320 allergy & immunology providers in New York.

Other allergy & immunology in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →